Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Chubb
Fish and Richardson
Farmers Insurance
Express Scripts
Merck
Citi
US Department of Justice
Daiichi Sankyo

Generated: April 21, 2018

DrugPatentWatch Database Preview

Nextwave Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for NEXTWAVE PHARMS, and what generic alternatives to NEXTWAVE PHARMS drugs are available?

NEXTWAVE PHARMS has one approved drug.

There are seven US patents protecting NEXTWAVE PHARMS drugs.

There are twenty-five patent family members on NEXTWAVE PHARMS drugs in fourteen countries.

Summary for Nextwave Pharms
International Patents:25
US Patents:7
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Nextwave Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nextwave Pharms QUILLIVANT XR methylphenidate hydrochloride FOR SUSPENSION, EXTENDED RELEASE;ORAL 202100-001 Sep 27, 2012 RX Yes Yes 8,778,390 ➤ Try a Free Trial Y ➤ Try a Free Trial
Nextwave Pharms QUILLIVANT XR methylphenidate hydrochloride FOR SUSPENSION, EXTENDED RELEASE;ORAL 202100-001 Sep 27, 2012 RX Yes Yes 8,956,649 ➤ Try a Free Trial Y ➤ Try a Free Trial
Nextwave Pharms QUILLIVANT XR methylphenidate hydrochloride FOR SUSPENSION, EXTENDED RELEASE;ORAL 202100-001 Sep 27, 2012 RX Yes Yes 9,040,083 ➤ Try a Free Trial Y ➤ Try a Free Trial
Nextwave Pharms QUILLIVANT XR methylphenidate hydrochloride FOR SUSPENSION, EXTENDED RELEASE;ORAL 202100-001 Sep 27, 2012 RX Yes Yes 8,465,765 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for NEXTWAVE PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Oral Suspension 5 mg/mL ➤ Subscribe 2013-08-02

Non-Orange Book US Patents for Nextwave Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,491,935 Modified release formulations containing drug-ion exchange resin complexes ➤ Try a Free Trial
8,597,684 Modified release formulations containing drug-ion exchange resin complexes ➤ Try a Free Trial
8,747,902 Modified release formulations containing drug-ion exchange resin complexes ➤ Try a Free Trial
8,202,537 Modified release formulations containing drug-ion exchange resin complexes ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Covington
US Army
UBS
Colorcon
Cantor Fitzgerald
Cipla
Express Scripts
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.